Entities / Company
Abeona Therapeutics.
biopharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 33
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
-
Abeona Therapeutics' therapy launch is being supported by a HUB partnership and patient-centric solutions.Some support1 report2 developments inside
-
Abeona Therapeutics collaborates with the University of Texas Medical Branch on clinical trials and patient care.Some support1 report
-
Abeona Therapeutics received FDA approval, enabling commercial launch and securing an NDRA agreement for expedited coverage from CMS.Well supported3 reports1 development inside
-
Abeona Therapeutics listed on the Nasdaq stock exchange, and its SVP sold company shares on July 1, 2026.Some support2 reports
Gone quiet
No new reports in 90+ days-
Abeona Therapeutics published the results of its VIITAL study in the medical journal The Lancet on June 24, 2025.Speculative1 report
-
Abeona Therapeutics was added to the Russell 2000 and Russell 3000 indices on June 30, 2025.Speculative1 report
-
Beacon Therapeutics exercised its option to license Abeona Therapeutics' capsid on July 1, 2025.Speculative1 report
-
Abeona Therapeutics received FDA review of its BLA resubmission for pz-cel on July 1, 2025, and was listed under Nasdaq Rule 5635(c)(4).Speculative1 report
-
Abeona Therapeutics commercialized ZEVASKYN therapy and partnered with Stanford Medicine and Lucile Packard Children’s Hospital to treat RDEB patients.Some support2 reports
-
ZEVASKYN, a gene therapy developed by Abeona Therapeutics, has received FDA approval.Some support3 reports
-
The cell sheet gene therapy market is seeing leading players supported by regulatory bodies and the progressive environment of Japan.Some support1 report
-
Abeona Therapeutics is maintaining a manufacturing facility in Cleveland.Some support3 reports
No events began in the chosen period. Widen it, or reset.
Around Abeona Therapeutics this week
News at the entities that move Abeona Therapeutics most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Abeona Therapeutics
-
Nasdaq StructuralApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Abeona Therapeutics
-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves Abeona Therapeutics
-
Royal Bank of Canada StructuralRoyal Bank of Canada raised its holdings in the Dimensional US Sustainability Core 1 ETF on June 19, 2026.Moves Abeona Therapeutics
-
Cleveland Shared contextDiscussions are underway regarding the impact of police killings involving Madison and Cleveland.Moves Abeona Therapeutics
Connections
The 7 strongest of 33, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
Abeona Therapeutics' commercial viability and function are structurally dependent on regulatory approvals and oversight provided by the FDA.
-
Nasdaq Structural
Abeona Therapeutics operates as a publicly traded company listed on the Nasdaq stock exchange.
-
SEC Structural
Abeona Therapeutics is subject to regulatory oversight and disclosure requirements mandated by the SEC.
-
Royal Bank of Canada Structural
RBC holds an investment stake in Abeona Therapeutics.
-
Cleveland Shared context
Abeona Therapeutics maintains a manufacturing facility located in Cleveland.
-
University of Texas Medical Branch Operational
Abeona Therapeutics and UTMB actively collaborate on clinical trials and patient care.
-
Brendan O’Malley Transactional
The individual (B) who was SVP of the company (A) executed a share sale on 2026-07-01.
History
Events by the month they beganAugust 2026
1 eventJuly 2026
1 eventJune 2026
10 events- Abeona Therapeutics' therapy launch is being supported by a HUB partnership and patient-centric solutions.
- Abeona Therapeutics received FDA approval, enabling commercial launch and securing an NDRA agreement for expedited coverage from CMS.
- Abeona Therapeutics published the results of its VIITAL study in the medical journal The Lancet on June 24, 2025.
- Abeona Therapeutics was added to the Russell 2000 and Russell 3000 indices on June 30, 2025.
- Beacon Therapeutics exercised its option to license Abeona Therapeutics' capsid on July 1, 2025.
- Abeona Therapeutics received FDA review of its BLA resubmission for pz-cel on July 1, 2025, and was listed under Nasdaq Rule 5635(c)(4).
- Abeona Therapeutics commercialized ZEVASKYN therapy and partnered with Stanford Medicine and Lucile Packard Children’s Hospital to treat RDEB patients.
- ZEVASKYN, a gene therapy developed by Abeona Therapeutics, has received FDA approval.
- The cell sheet gene therapy market is seeing leading players supported by regulatory bodies and the progressive environment of Japan.
- Abeona Therapeutics is maintaining a manufacturing facility in Cleveland.